Companion Medical announced clearance by the FDA for the use of Novo Nordisk's Fiasp® rapid-acting insulin. The clearance adds to its existing solutions for managing insulin-dependent diabetes, which to date has supported Humalog® and Novolog®.
Fiasp® is indicated for dosing at mealtime, or within 20 minutes after starting a meal, and is recommended for patients who need dose timing flexibility or who tend to dose late. "Companion Medical's goals are to create affordable, easy-to-use solutions that allow people with diabetes to focus more on their lives and less on their condition," said Sean Saint, Chief Executive Officer of Companion Medical. "Our customers tell us that the InPen system has changed their lives and indicating another rapid-acting insulin allows us to expand to more people living with diabetes, including those who want more dose timing flexibility."
InPen is available in the U.S. by prescription only. The app is available for download on the Apple® App Store and Google Play™.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!